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bstract
To determine the impact on minimal residual disease by switching to imatinib chronic phase chronic myeloid leukaemia (CP-CML) patients
esponsive to interferon-alpha (IFN), in stable complete cytogenetic response (CCR) but with persistent PCR positivity.
Twenty-six Philadelphia positive (Ph+) CML patients in stable CCR after IFN but persistently positive at PCR analysis during this
reatment, were given imatinib mesylate at standard dose.
At enrolment into the study, median IFN treatment and CCR duration were 88 months (range 15–202) and 73 months (range 10–148),
espectively. Imatinib treatment resulted in a progressive and consistent decline of the residual disease as measured by quantitative PCR
RQ-PCR) in all but one of the 26 patients; at the end of follow-up, after a median of 32 months (range 21–49) of treatment, a major
olecular response (BCR/ABL levels <0.1) was reached in 20 patients (77%), and BCR/ABL transcripts were undetectable in 13 (50%). The
chievement of molecular response was significantly correlated with post-IFN baseline transcript level (mean 1.194 for patients achieving
omplete molecular response versus 18.97 for those who did not; p < 0.001), but not with other clinical/biological disease characteristics.These results indicate that patients induced into CCR by IFN treatment represent a subset with very favourable prognosis, which can
ignificantly improve molecular response with imatinib and further support investigative treatment schedules combining these two drugs.
2007 Elsevier Ltd. All rights reserved.
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r
i. Introduction
Chronic myeloid leukemia (CML) is a malignant
ematopoietic disease whose molecular hallmark is the
CR/ABL gene rearrangement originating from a t(9;22)
ranslocation. The BCR/ABL fusion product encodes for
∗ Corresponding author at: Department of Cellular Biotechnologies and
ematology, Via Benevento 6, 00161 Rome, Italy.
E-mail address: alimena@bce.uniroma1.it (G. Alimena).
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oi:10.1016/j.leukres.2007.06.008deregulated tyrosine kinase (TK), which has a central
ole in the pathogenesis of the disease [1]. Until recently,
nterferon- (IFN) was considered the gold standard for
rug therapy of CML, as it yielded complete cytogenetic
esponse (CCR) in 10–25% of patients with significant sur-
ival prolongation, particularly in low risk patients usually
btaining a higher response rate [2,3]. However, even in best
esponding patients, the disease still remained detectable at
molecular level, and the majority of patients eventually
elapsed [4–7]. Only consistently negative RT-PCR patients
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ppeared to remain 100% in CCR at 10 years follow-up
7].
The introduction of imatinib mesylate (STI571, Gleevec),
selective inhibitor of the BCR/ABL TK, has revolu-
ionized the disease management, as it induces CCR in
0–90% of chronic phase (CP) CML patients, including
hose resistant or refractory to IFN [8,9]. Furthermore,
olecular monitoring using quantitative PCR (RQ-PCR) has
hown a consistent reduction of the transcript level in a
igh proportion of responder patients, and the degree of
he molecular response strongly correlates with the prob-
bility of progression-free survival. A reduction of the
CR/ABL transcript level ≥3 log at 12 or 18 months pre-
icts almost 100% long-term remission [8–12]. However,
esidual disease still remains detectable using PCR stan-
ard procedures in the majority of patients, and development
f imatinib resistance is the main cause of therapy failure
11–17].
In this study, we administered standard dose imatinib to 26
ML patients in late CP, who were in stable CCR induced by
FN, but had persistent residual disease by molecular analy-
is. We monitored the level of BCR/ABL fusion transcript by
Q-PCR to assess the impact on residual disease of crossover
rom IFN to imatinib in this subset of IFN-responding patients
nd the possible correlations between response to imatinib
nd clinical-biological characteristics of patients at diagnosis
nd during follow-up.
. Materials and methods
.1. Patients and study design
Twenty-six Ph+ CP-CML patients who had been diag-
osed in our institutions between December 1985 and March
000 entered this study. Inclusion criteria were: (a) having
eceived an IFN based treatment, (b) being in stable CCR
efined as the absence of Ph+ mitoses in at least two con-
ecutive analyses (6 months apart), and (c) being persistently
ositive at qualitative PCR analysis for the BCR/ABL tran-
cript.
At presentation all patients were previously untreated
nd in first CP according to the standard criteria [18].
ll patients had been receiving IFN from diagnosis at
he maximum tolerated dose (up to 5 MU/m2/day); follow-
ng CCR, the initial IFN scheduled dosage was adjusted
o maintain WBC count between 1.5 and 4 × 109 L−1.
rom the time of imatinib treatment, quantitative PCR
nalysis of residual disease was regularly assessed. A reduc-
ion in the dose of imatinib because of non-hematologic
r hematologic toxicities was allowed according to com-
on toxicity criteria [18]. Complete blood counts anderum chemistry evaluations were performed before start-
ng imatinib, weekly during the first 6 weeks, every 2
eeks for the next 6 weeks, and every 6 months there-
fter.
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.2. Cytogenetics
Cytogenetic analyses were performed on bone marrow
BM) aspirates at diagnosis, every 6 months during IFN treat-
ent, before starting imatinib (baseline), and after 3, 6, and
2 months of therapy and thereafter every 6 months, accord-
ng to standard methods. Only results obtained from at least
0 metaphases were considered as evaluable. Cytogenetic
esponse was categorized according to standard criteria [2]:
CR was defined as the presence of 100% Ph- metaphases.
.3. FISH analysis
FISH analysis was performed on unseparated nucle-
ted cells using differently labeled BCR and ABL probes
LSI BCR/ABL ES Dual Color Translocation Probe, Abbott
olecular Diagnostics) with a minimum of 150 cells in inter-
hase being scored for each sample. Normal cells display
wo red signals (ABL gene) and two green signals (BCR
ene), while the FISH pattern of Ph positive cells consists
f one red, one green and two yellow signals. The cut-off
imit for BCR/ABL positive analysis was set at 0.2%, i.e. the
ean + 2 S.D. of positive FISH pattern detected by scoring
000 nuclei of bone marrow cells from patients affected by
ther hemopoietic diseases.
.4. Quantitative evaluation of minimal residual disease
.4.1. Organization, sampling schedule and storage of
amples
Quantitative assays of minimal residual disease (MRD)
ere centrally performed in Naples at the CEINGE-
iotecnologie Avanzate [19]. BM samples for MRD analysis
ere collected from all patients enrolled into the study prior to
matinib treatment (baseline), after 3, 6, 12 and 18 months;
further assay of MRD was also carried out at the latest
ollow-up.
.4.2. Cell separation and RNA extraction
Leukocyte pellets were isolated from BM aspirates by
ysis of red blood cells, and re-suspended in aliquots of
× 106 in 600L of 4 M guanidium isothiocyanate solu-
ion (GITC). Total RNA was extracted using ion exchange
hromatography on minicolumn (GeneElute, Total RNA
urification kit, Sigma, St. Louis, MO, USA), according to
he manufacturer directions.
.4.3. Real time quantitative RT-PCR assay of minimal
esidual disease
MRD was detected during follow-up by a recently stan-
ardized RQ-PCR method [20]. The method independently
easures in each sample by real time PCR, the copy num-er of both mRNA encoding for the P210 BCR/ABL protein
nd for Abelson (ABL); the latter was used as a control gene
o verify sample-to-sample RNA quality variations. In this
tudy, for each amplification run, both a BCR/ABL and ABL
ia Research 32 (2008) 255–261 257
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Table 2
Patient features
Number of patients 26
Age
Mean (years) 40
Range 21–64
Sokal Risk
Low 18
Intermediate 8
High –
Follow-up (months)
Median 122
Range 49–236
IFN- treatment
Duration (months)
Median 88
Range 15–202
Weekly dose (MU)
Median 26
Imatinib treatment
Duration (months)
Median 32
Range 21–49
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tandard curve were independently generated by assaying, in
arallel with the samples, 1:10 serial dilutions (from 106 to
02 copies, each in triplicate) of plasmid DNA calibrators
ontaining the target sequences diluted in a solution of E.
oli RNA (20 ng/L). The copy number (CN) of BCR/ABL
nd ABL transcript are derived by the interpolation of the
ycle threshold (Ct—the number of PCR cycles necessary to
etect a signal above the threshold) values to the appropri-
te standard curve; the result for each sample was expressed
s ratio of BCR/ABL mRNA copies to ABL mRNA × 100
normalized copy number—NCN).
.4.4. Real Time quantitative PCR reaction conditions
The reaction conditions were the same for both BCR/ABL
nd ABL mRNA RQ-PCR. Briefly, 1g of total RNA
xtracted from the patient samples was pre-warmed for
0 min at 70 ◦C and incubated for 10 min at 25 ◦C; the
NA solution was then incubated for 42 min at 45 ◦C in a
0L reaction mixture containing 10 mM Tris–HCl (pH 8.3),
0 mM KCl, 5.5 mM MgCl2, 1 mM of each deoxyribonu-
leotide, 20 U of RNAsin (Pharmacia, Upsala, Sweeden),
5 mM random examers (Pharmacia), 10 mM of DTT (Phar-
acia), and 100 U of MoMLV reverse transcriptase (BRL,
ethesda, MD). PCR amplification of p210- and ABL-
ncoding cDNAs were separately carried out in a reaction
ixture consisting of 1 × Master Mix (Applied BioSystem,
oster City, CA USA), 300 nM of the appropriate primer
air and 200 nM of the appropriate probe in a final vol-
me of 25L using the following time/temperature profile:
5 ◦C, 15 s, and 60 ◦C, 1 min, for 50 cycles. All amplifi-
ation reactions were carried out in triplicate. Primers and
robe sequences for RQ-PCR of BCR/ABL and ABL were
esigned, tested and standardized within the EU concerted
ction (Table 1). Plasmid dilution used to generate the stan-
ard curves of the assays, were purchased by IPSOGEN Inc.
Marseille, France).
Sample results and all analytical series underwent to a
igorous check, as follow: (i) RNA samples that repeatedly
ave ABL Ct values higher than 28.7 were operationally con-
idered degraded and eliminated from further evaluation to
nsure a sensitivity of at least 4 logs in all samples assayed;
ii) in the case of BCR/ABL Ct value higher than the intercept
alue of the relative standard curve of the run (Ct value corre-
ponding to one copy), the samples were considered negative
MRD below the detection limit of the technique); (iii) in the
ase that the slope of a standard curve was not comprised
a
b
d
able 1
equences of primers and probes used for the assay of BCR/ABL and ABL mRNA
Sequence (5′ → 3′)
NF501 TCCGCTGACCATCAACAAGGA
NP541 Fam-CCCTTCAGCGGCCAGTAGCAT
NR561 CACTCAGACCCTGAGGCTCAA
NF1302 GAGTATGCCTGCCGTGTG
NPr1342 Fam-CCTCCATGATGCTGCTTACAT
NR1362 AATCCAAATGCGGCATCTDaily dose (mg)
Median 400
ithin the mean ±2 standard deviations, all the samples of
he analytical series were re-assayed.
.5. Statistics
Statistical analysis was performed using SPSS version
.0 software; Wilcoxon–Mann–Whitney test was performed
or comparison of non-parametric series and Fisher’s exact
est was used to compare categories. Values of p < 0.05 were
onsidered of statistical significance.
. Results
.1. Pre-Imatinib features of patients
Clinical features of the 26 patients enrolled into the study
re summarized in Table 2.
At diagnosis median age was 40 years (range 21–64), and
aseline Sokal risk score was low in 18 patients and interme-
iate in the remaining 8, whereas no patient was in high risk
levels
Description
Sense—BCR exon 13
CTGA-Tamra Probe—ABL exon 2
Antisense—uABL exon 2
Sense—ABL exon 2
GTCTC-Tamra Probe—ABL exon 3
Antisense—ABL exon 4
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Fig. 1. MRD levels at baseline and at end of follow-up. MRD levels assessed
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molecular response) (Fig. 2). In a single patient, MRD levely RQ-PCR in patients at IFN treatment discontinuation before imatinib
herapy and at the end of the follow-up. Dotted lines indicate median values
f the two groups of MRD values.
ategory. Overall, median weekly dose of IFN received from
he patients was 26 MU, the median duration of IFN treatment
eing 88 months (range 15–202). All the 26 patients had sus-
ained CCR from a median of 73 months (range 10–148)
t the start of imatinib. Total follow-up from diagnosis of
he patients was 122 months (range 49–236). During the
ourse of IFN treatment, qualitative RT-PCR analysis tested
lways positive for all the patients. At the end of IFN treat-
ent, median BCR/ABL transcripts level in BM samples
f patients, assayed by RQ-PCR analysis, was 0.89 (range
.06–100.04), and was considered as study baseline level
f MRD (see Fig. 1). In three patients, RQ-PCR showed
level of MRD higher than 10, despite the confirmed sta-
us of CCR. Therefore, FISH analysis was performed on
nterphase marrow cells of patients given the possible pres-
nce, in the marrow of the three patients, of Ph positive
ells still inhibited by IFN in their capability to prolifer-
te in vitro. Consistently with the RQ-PCR data, all these
atients had up to 8% of analyzed nuclei positive for the
CR/ABL translocation, thus suggesting the possibility of
n impending disease relapse (Table 3). None of the other
atients had BCR/ABL positive cells detectable by interphase
ISH.
able 3
ISH analysis of the three patients with high MRD level at the treatment
witch to Imatinib
atient IFN treatment
duration (months)
MRD
level
Interphase
FISH
Analyzed
nuclei
BCR/
ABL+ve
(%)
1 202 52.84 291 8
2 66 100.04 190 7
3 96 20.77 290 2
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.2. Imatinib treatment
Imatinib treatment was well tolerated by all 26 patients;
o patient needed dose reduction or drug discontinuation
or hematological or extra hematological side effects. At the
resent time, after a median of 37 months (range 26–54) of
linical observation, all patients are still on imatinib treat-
ent at the full 400 mg/die dose. No patient showed loss of
ither hematological or cytogenetic complete response. Over-
ll, total follow-up from diagnosis of the 26 patients is 122
onths (range 49–236).
Imatinib treatment induced in all but one patient a sig-
ificant decrease of MRD level: median BCR/ABL ratio
eached <0.01, a level more than two-log lower with respect
o the baseline post-IFN value (Fig. 1). Noteworthy, 20
atients (77%) had PCR results below 0.1%, with 13 of them
50%) being in complete response (BCR/ABL transcript not
etectable by PCR) (Table 4). The levels of MRD at the end
f follow-up did not correlate with overall disease length,
FN treatment duration and the Sokal risk at presentation
data not shown). Conversely, the levels of MRD reached
fter IFN (baseline level in this study) of the 13 patients who
btained complete molecular response under imatinib were
ignificantly lower than those of the remaining patients (1.194
ersus 18.97, p < 0.001). Sensitivity of PCR analysis was
ssessed as previously published in single patient samples
19] to avoid any influence on results by sample degrada-
ion. Mean ABL copy number of the analyzed samples was
500 (range 1300–48,000) with a calculated sensitivity of
he assays never lower than 10−4, and in the case of samples
ho gave negative PCR results the mean ABL copy number
as 7200 (range 1300–21,100). Overall, MRD monitoring
Fig. 2) showed a progressive decline of median values over
he various time points, thus indicating a continuous reduc-
ion of the leukemic burden. Remarkably, the response to
matinib treatment was very rapid in a significant proportion
f patients; MRD level was evaluable in 18 samples after the
rst 3 months of imatinib treatment, and in seven of these
CR/ABL transcripts were no longer detectable (PCR neg-
tive), while in other two the level was below 0.1 (majorhowed almost one log increase at the last follow-up. This
atient had, at presentation, an intermediate Sokal risk of
rogression, and, at start of imatinib treatment, more than 15
able 4
inimal residual level by RQ-PCR of BCR/ABL in the 26 patients
Baseline Last follow-up
eana 10.51 0.09
ediana 0.89 0.01
angea 0.06–100.04 0–1.02
RD <0.1 (no.) 1 20b
CR negative (no.) – 13c
a Value expressed as BCR/ABL-ABL ratio%.
b Including the 13 PCR negative patients.
c Baseline MRD level of these patients was 1.194 vs. 18.97 (p < 0.001) of
he remaining patients.
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lig. 2. Progressive effect of imatinib on MRD level. Representation of the
rogressive decline of MRD levels observed in CML patients under imatinib
reatment. Dotted lines indicate median values of MRD at single time points.
ears of IFN therapy with an overall follow-up duration of
20 months.
. Discussion
In the present study, we analysed the effect of switch-
ng to imatinib 26 CML patients with long term cytogenetic
ut not molecular response to IFN. The main reason for this
herapeutical decision was to evaluate whether a stable cyto-
enetic response to IFN could be improved at the molecular
evel through the possible complementary actions of the two
rugs.
We found that 77% of our patients treated with a stan-
ard dose of imatinib reached BCR/ABL levels <0.01 over
median follow-up period of 32 months. These data were
btained from an unusual subset of selected patients; there-
ore, they cannot be extrapolated to the general CML patient
opulation. However, some considerations may be done.
sing IFN, 10–25% of CP-CML patients obtain CCR, but
nly a minority of them achieve and maintain very low
evels of residual disease and do not experience disease
elapse or progression [4–7,21,22]. When imatinib is given
t 400–800 mg/day, CCR is obtained in 50 to >90% of
atients with new diagnosis or late CP-CML, including
hose pre-treated with IFN [9,23,24]. Furthermore, molecular
onitoring by quantitative RQ-PCR, has shown consis-
ent reduction of the transcript level in a high proportion
f responder patients, and the degree of the molecular
esponse strongly correlates with the probability of long-term
rogression-free survival [12,17,24]. However, transcript
ndetectability only reached a limited number of patients.
he dynamics of the molecular response has been analysedn large series of patients in CCR after imatinib, the percent-
ge of cases with undetectable transcripts ranging from 4 to
% to near 40% of the cases, depending on disease status (late
r early CP), prior IFN treatment or not, imatinib dosage (400
p
[
p
rarch 32 (2008) 255–261 259
r 800 mg/day) [9,23]. Therefore, the heterogeneity of pre-
iously investigated cases precludes direct comparison with
he data obtained from the present study.
In our series of selected patients in minimal disease status,
he molecular response was very rapid and residual disease
ndetectability was achieved in a high proportion of patients.
urthermore, transcript reduction in almost all our patients
ppeared to be sustained, and progressively increasing over
ime, thus indicating ongoing disease depletion, as previously
bserved [9,12,13]. Also the three patients who had a high
RD level following IFN treatment showed a rapid decline of
he BCR/ABL transcript levels as assessed by RQ-PCR. This
ubset of patients with a high level of BCR/ABL transcript
as already indicated in the IFN era as candidate for an immi-
ent relapse [4]; noteworthy, these three subjects showed
small percentage (2–8%) of BCR/ABL positive nuclei at
ISH analysis and they were likely going into relapse.
Despite being in late disease, our patients obtained
mproved molecular response on imatinib. This apparently
ontrasts with the observations that better results are usually
eached in earlier disease due to the enhanced probability of
eveloping imatinib-resistant mutations over time [9,16,25].
e could thus infer that the significant reduction of the
CR/ABL positive cells induced by IFN made the devel-
pment of resistance less likely to occur in our patients.
lternatively, some biological factors may exist in this sub-
et of patients with particularly good prognosis, capable of
reventing clonal evolution. We only observed a rough cor-
elation between the baseline (post-IFN) level of BCR/ABL
ranscripts and the degree of molecular response under ima-
inib, while we did not find, in our series of patients, a
orrelation between molecular response to imatinib and dis-
ase duration, length and weekly dose of IFN, and Sokal
core. It should be underlined that no high Sokal risk patient
as included in our study group, may be as a consequence of
he unsatisfactory response to IFN usually seen in this sub-
et of CML patients. The prognostic impact of high Sokal
isk was also confirmed in imatinib era by large coopera-
ive clinical trials: the CCR rate in this subgroup of patients
ever exceeds 70% even under high dose imatinib treat-
ent [17,23]. Finally, the mechanisms by which imatinib
mproved molecular status in our IFN-responsive patients
emain to be elucidated. It is well known that these two
rugs act through different molecular mechanisms, and it
s thus expected that their effects may be mutually poten-
iated [26]. The complex action of IFN, which includes
irect antineoplastic effect and immunomodulatory activity,
s not fully understood [26]. However, it has been sug-
ested that it induces control, rather than eradication, of the
isease [27]. In contrast, imatinib and the new generation
K inhibitors act directly on the oncogenic protein of the
eukemic clone; however even imatinib may fail to com-
letely eliminate primitive quiescent Ph+ progenitor cells
27]. Thus, it is possible that IFN and imatinib exerted a com-
lementary effect in our patients, while showing no cross drug
esistance.
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Much has been discussed about curtailing treatment in
atients with persistent CCR after IFN, given that very low
umber of Ph+ cells does not necessarily imply relapse, and
hat patients with molecularly negative disease do not seem
o experience relapse [5,6,7]. This issue applies now also to
atients in CCR after imatinib, especially to those achieving
ersistently undetectable levels of residual disease, in whom
ivergent outcome have been observed after imatinib discon-
inuation [28]. Furthermore, as a high number of patients
n CCR on imatinib still remain molecularly positive and at
otential risk of relapse, strategies aiming at increasing PCR
egativity need to be explored, which include combining or
dding synergistic drugs to imatinib [29].
The concurrent use of imatinib and IFN has been recently
tudied in multicenter trials but results have demonstrated
dditive cytotoxic effects, limiting the possibility to apply
his approach in the clinical practice [26]. Though the use
f imatinib is at present the first choice for CML therapy,
he complementary actions of the two drugs could be investi-
ated in sequential or low-dose combination, also in patients
eaching stable CCR on imatinib but still having detectable
olecular disease.
Longer follow-up and strict monitoring of these patients,
ith improving technologies over time is required to deter-
ine to what extent they will become molecularly negative
nd whether patients with undetectable transcripts are indeed
ured of their disease.
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